[抗血脂药的药代动力学。5. 2-(4-羟基苯氧基)-2-甲基丙酸是抗血脂药环丙贝特的一种代谢产物吗？]
[The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
作者信息
Oelschläger H, Rothley D, Hellwich K H, Schmidt W
出版信息
Arch Pharm (Weinheim). 1989 Jun;322(6):337-42. doi: 10.1002/ardp.19893220603.
PMID:2774869
Abstract
After oral administration of Ciprofibrate (1) to volunteers (n = 5) only its glucuronide, but no 1 and no 2-(4-Hydroxyphenoxy)-2-methyl-propionic acid (3) could be detected in the fresh urine. Its formation from 1 seems to be impossible on the basis of established biochemical reactions. Therefore, its presence in the urine of volunteers reported by other authors is refuted.
摘要
在给志愿者（n = 5）口服环丙贝特（1）后，在新鲜尿液中仅检测到其葡萄糖醛酸苷，未检测到1以及2-(4-羟基苯氧基)-2-甲基丙酸（3）。基于已确定的生化反应，由1形成它似乎是不可能的。因此，其他作者报道的志愿者尿液中它的存在被驳斥。
相似文献
1
[The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].[抗血脂药的药代动力学。5. 2-(4-羟基苯氧基)-2-甲基丙酸是抗血脂药环丙贝特的一种代谢产物吗？]
Arch Pharm (Weinheim). 1989 Jun;322(6):337-42. doi: 10.1002/ardp.19893220603.
2
[Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].[降血脂药的药代动力学。4. 降血脂药环丙贝特（2-(4-(2,2-二氯环丙基)-苯氧基)-2-甲基丙酸）的生物转化]
Arch Pharm (Weinheim). 1988 Jun;321(6):367-70. doi: 10.1002/ardp.19883210615.
3
[The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].[降血脂药物的药代动力学。6. 2-(4-(2,2-二氯环丙基)-苯氧基)-丙烷是降血脂药物环丙贝特的代谢产物吗？]
Arch Pharm (Weinheim). 1989 Oct;322(10):629-32. doi: 10.1002/ardp.19893221011.
4
The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.肾功能不全和血液透析对环丙贝特动力学的影响。
Br J Clin Pharmacol. 1989 Dec;28(6):675-81. doi: 10.1111/j.1365-2125.1989.tb03560.x.
5
[The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate].[降血脂药物的药代动力学。10. 降血脂药物环丙贝特的脱卤反应]
Arch Pharm (Weinheim). 1994 Apr;327(4):261-5. doi: 10.1002/ardp.19943270412.
6
[Conjugation reactions of ciprofibrate with human and laboratory animals].[环丙贝特与人及实验动物的结合反应]
Arzneimittelforschung. 2003;53(4):247-53. doi: 10.1055/s-0031-1297104.
7
The effect of ciprofibrate on gastric secretion in the rat.环丙贝特对大鼠胃分泌的影响。
J Pharm Pharmacol. 1988 Jul;40(7):512-3. doi: 10.1111/j.2042-7158.1988.tb05289.x.
8
Characterization of ciprofibrate and clofibric acid as peroxisomal proliferators in primary cultures of rat hepatocytes.环丙贝特和氯贝酸在大鼠原代肝细胞培养物中作为过氧化物酶体增殖剂的特性研究。
Hepatology. 1987 May-Jun;7(3):508-16. doi: 10.1002/hep.1840070316.
9
Metabolic effects of a new hypolipidemic agent, ciprofibrate.一种新型降血脂药物环丙贝特的代谢作用
J Pharm Sci. 1979 Dec;68(12):1557-8. doi: 10.1002/jps.2600681227.
10
[Amino acid derivatives of 2-(p-chlorophenoxy)-2-methylpropionic acid as compounds with potential antilipemic agents. II. Preparation of methyl esters of N-[2-(p-chlorophenoxy)-2-methylpropionyl] amino acids].[2-(对氯苯氧基)-2-甲基丙酸的氨基酸衍生物作为潜在抗血脂剂的化合物。II. N-[2-(对氯苯氧基)-2-甲基丙酰基]氨基酸甲酯的制备]
Acta Pol Pharm. 1987;44(2):121-31.
Zotero 插件